Sana Biotechnology (NASDAQ:SANA) Shares Climb 5.9% - Time to Buy?

Sana Biotechnology logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Sana Biotechnology shares rose 5.9% to about $1.99, but trading volume was roughly 95% below its average.
  • Analysts’ consensus rating is “Moderate Buy”, with an average price target of $9.83; ratings range from one Strong Buy and six Buys to one Hold and one Sell.
  • The company reported a quarterly loss of $0.14 per share, narrowly beating estimates of a $0.15 loss. Institutional investors own 88.23% of shares, with several large firms having established positions.
  • Interested in Sana Biotechnology? Here are five stocks we like better.

Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) was up 5.9% during trading on Wednesday. The stock traded as high as $1.95 and last traded at $1.9910. Approximately 166,184 shares changed hands during trading, a decline of 95% from the average session volume of 3,160,180 shares. The stock had previously closed at $1.88.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Weiss Ratings cut shares of Sana Biotechnology from a "sell (d-)" rating to a "sell (e+)" rating in a report on Wednesday, November 11th. TD Cowen upgraded shares of Sana Biotechnology to a "strong-buy" rating in a research report on Monday, August 24th. Wall Street Zen raised shares of Sana Biotechnology from a "sell" rating to a "hold" rating in a research note on Saturday, November 7th. Bank of America cut their target price on shares of Sana Biotechnology from $7.00 to $6.00 and set a "buy" rating on the stock in a research report on Friday, August 14th. Finally, Citigroup decreased their target price on shares of Sana Biotechnology to $11.00 and set a "buy" rating on the stock in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Sana Biotechnology presently has an average rating of "Moderate Buy" and a consensus price target of $9.83.

View Our Latest Stock Report on Sana Biotechnology

Sana Biotechnology Stock Performance

The stock's fifty day simple moving average is $2.65 and its two-hundred day simple moving average is $3.26. The stock has a market capitalization of $564.82 million, a P/E ratio of -3.58 and a beta of 2.30.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.01. As a group, analysts expect that Sana Biotechnology, Inc. will post -0.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sana Biotechnology

Several institutional investors and hedge funds have recently made changes to their positions in SANA. BlackRock Inc. acquired a new stake in Sana Biotechnology during the 2nd quarter worth about $58,196,000. Canada Pension Plan Investment Board acquired a new stake in Sana Biotechnology during the second quarter worth approximately $35,662,000. Bank of America Corp DE bought a new stake in Sana Biotechnology in the second quarter worth approximately $20,062,000. Alphabet Inc. bought a new stake in Sana Biotechnology in the second quarter worth approximately $9,816,000. Finally, Deutsche Bank AG acquired a new position in Sana Biotechnology in the second quarter valued at approximately $2,251,000. Institutional investors and hedge funds own 88.23% of the company's stock.

About Sana Biotechnology

(Get Free Report)

Sana Biotechnology, Inc. is a clinical-stage biotechnology company founded in 2018 and headquartered in Seattle. It develops engineered cells intended to treat a range of diseases, including cancer, autoimmune disorders and conditions that may be addressed through cell replacement. The company's research focuses on modifying cells to improve their therapeutic properties, including approaches designed to help transplanted cells evade immune rejection. Its programs include engineered immune-cell therapies and cell-replacement treatments, such as work involving insulin-producing cells for type 1 diabetes.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Sana Biotechnology Right Now?

Before you consider Sana Biotechnology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sana Biotechnology wasn't on the list.

While Sana Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines